REPORT: Former GOP Lawmaker Sentenced to Prison for Insider Trading Case

JANUARY 17, 2020

Below is a report that DML News gives a 4 OUT OF 4 STARS trustworthiness rating. We base this rating on the following criteria:

  • Provides named sources
  • Reported by more than one notable outlet
  • Does not insert opinion or leading words
  • Includes supporting video, direct statements, or photos

Click here to read more about our rating system.

As the most reliable and balanced news aggregation service on the internet, DML News App offers the following information published by NYTimes.com:

Representative Chris Collins had told so many people, from fellow House members to friends and relatives, about a surefire investment: a little-known Australian drug company that was developing a treatment for multiple sclerosis.

But when Mr. Collins learned about a critical drug trial that had failed, he set in motion a chain of events that led to a federal indictment, the end of his career in Congress and, on Friday, a 26-month prison sentence and a $200,000 fine.

The article goes on to state the following:

The judge, Vernon S. Broderick of Federal District Court in Manhattan, said that Mr. Collins had a higher obligation to obey the law, given his position in the House and on the board of the drug company, and that he had committed a crime that in many ways went to the heart of the country’s financial system.

The report states that Collins, 69, who was the first sitting member of Congress to endorse Donald Trump during his 2016 campaign, delivered statement before he was sentenced, sobbing at times, as he apologized to those he had hurt, including his family, his constituents, his former colleagues in Congress, and President Trump.

“What I’ve done has marked me for life. I stand here today as a disgraced former member of Congress that will have that asterisk by my name,” Collins said.

CLICK HERE to read more.

To get more information about this article, please visit NYTimes.com. To weigh in, leave a comment below.

Trending on DML News

Leave a comment

Your email address will not be published. Required fields are marked *